Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533471 | 0.91 | CA1 (0.50) | EPHX1DNM1CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL10856379 | 0.88 | DNM1 (0.48) | EPHX1DNM1CA1CA2CA12 | |
| SCHEMBL3633166 | 0.86 | DNM1 (0.48) | EPHX1DNM1CA1CA2CA12 | |
| SCHEMBL319971 | 0.83 | EPHX1 (0.71) | EPHX1KDM4CKDM4EMEN1KMT2A | |
| SCHEMBL21529732 | 0.80 | CYP2C9 (0.52) | EPHX1DNM1CA1CA2CA12 | |
| SCHEMBL836639 | 0.79 | PRMT3 (0.46) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL20972405 | 0.78 | EPHX1 (0.63) | EPHX1DNM1KDM4E | |
| SCHEMBL19849365 | 0.78 | DNM1 (0.42) | EPHX1DNM1CA1CA2CA12 | |
| SCHEMBL5779247 | 0.78 | EPHX1 (0.65) | EPHX1KDM4CKDM4EMEN1KMT2A | |
| Dimethylamine SCHEMBL10414531 | 0.78 | EPHX1 (0.65) | EPHX1KDM4CKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022075347-A1 | METHOD FOR PRODUCING OCTAHYDROTHIENOQUINOLINE COMPOUND, AND PRODUCTION INTERMEDIATE OF SAME | キッセイ薬品工業株式会社 | 2022-04-14 | — | — | WO | disclosed |
| US-10266484-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180065920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2018-03-08 | — | — | US | disclosed |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080132500-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-06-05 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266484-B2 | Biodegradable lipids for the delivery of active agents | LIPA, CETP, APOB | EPHX1 3557/4885DNM1 442/4885KDM4C 4330/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | EPHX1 2528/4885DNM1 854/4885KDM4C 4646/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | EPHX1 1955/4885DNM1 3431/4885KDM4C 4734/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | EPHX1 2034/4885DNM1 1858/4885KDM4C 980/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | EPHX1 2705/4885DNM1 1400/4885KDM4C 3261/4885 |
| US-20180065920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | EPHX1 3557/4885DNM1 442/4885KDM4C 4330/4885 |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, ABHD16A, CETP | EPHX1 3748/4885DNM1 984/4885KDM4C 3847/4885 |
| US-20080132500-A1 | Antibiotic compounds | NRDC, MRPL21, PEPD | EPHX1 4480/4885DNM1 1231/4885KDM4C 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.